Dabigatran etexilate
CAS No. 211915-06-9
Dabigatran etexilate( BIBR-1048 )
Catalog No. M13373 CAS No. 211915-06-9
A prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 30 | In Stock |
|
| 5MG | 47 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 50MG | 80 | In Stock |
|
| 100MG | 108 | In Stock |
|
| 200MG | 158 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDabigatran etexilate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM.
-
DescriptionA prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM; 10-fold less potent for Trypsin and no activity against Factor Xa, Plasmin, tPA and activated protein C; exhibits strong and long-lasting anticoagulant effects ex vivo and strong oral activity in different animal species.Thrombosis Approved(In Vitro):Dabigatran etexilate (BIBR 1048; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after administration, respectively.Dabigatran etexilate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively.Dabigatran etexilate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey.
-
In Vitro——
-
In VivoDabigatran etexilate (BIBR 1048; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after administration, respectively. Dabigatran etexilate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively.Dabigatran etexilate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey. Animal Model:Male rats (280-350 g) and rhesus monkeys of either sex (3-8 kg)Dosage:10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys Administration:Oral Result:Had dose- and time-dependent anticoagulant effects.
-
SynonymsBIBR-1048
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThrombin
-
Research AreaCardiovascular Disease
-
IndicationThrombosis
Chemical Information
-
CAS Number211915-06-9
-
Formula Weight627.7332
-
Molecular FormulaC34H41N7O5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(OCC)CCN(C1=NC=CC=C1)C(C2=CC=C3N(C)C(CNC4=CC=C(/C(N)=N\C(OCCCCCC)=O)C=C4)=NC3=C2)=O
-
Chemical Nameb-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hauel NH, et al. J Med Chem. 2002 Apr 25;45(9):1757-66.
2. Wienen W, et al. Thromb Haemost. 2007 Jul;98(1):155-62.
3. Baetz BE, et al. Pharmacotherapy. 2008 Nov;28(11):1354-73.
molnova catalog
related products
-
Melagatran
Melagatran is an orally available, direct synthetic thrombin inhibitor that does not require endogenous cofactors other than thrombin and does not significantly interact with any other enzymes in the coagulation cascade or with the fibrinolytic enzymes.
-
Flovagatran
Flovagatran (TGN 255) is an orally active, potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.
-
Naroparcil
Naroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).
Cart
sales@molnova.com